Novartis Releases Fourth Quarter and Full Year Financials

Pharmaceutical Investing

Novartis (NYSE:NVS) delivered good operational performance and landmark innovation in 2017, entering our next growth phase. As quoted in the release: Vas Narasimhan, designated CEO from February 1, commented: “I want to thank Joe and the Board for their leadership and guidance as I transition to my new role. As CEO my priorities will be …

Novartis (NYSE:NVS) delivered good operational performance and landmark innovation in 2017, entering our next growth phase.

As quoted in the release:

Vas Narasimhan, designated CEO from February 1, commented:
“I want to thank Joe and the Board for their leadership and guidance as I transition to my new role. As CEO my priorities will be driving our next growth phase by strengthening operational execution, delivering more breakthrough innovation, pivoting to become a data centric, digitally enabled organization, building trust and reputation and transforming our culture. I feel privileged to lead Novartis at this exciting time.”

Click here for the full release.

guidance novartis Pharmaceutical Investing